Compare DHX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHX | ACRV |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.1M | 82.7M |
| IPO Year | 2007 | 2022 |
| Metric | DHX | ACRV |
|---|---|---|
| Price | $1.59 | $2.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.75 | ★ $14.67 |
| AVG Volume (30 Days) | 283.2K | ★ 531.6K |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $131,236,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $805.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.21 | $1.05 |
| 52 Week High | $3.34 | $8.00 |
| Indicator | DHX | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 32.13 | 59.17 |
| Support Level | $1.69 | $2.44 |
| Resistance Level | $1.92 | $2.73 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 15.58 | 64.91 |
DHI Group Inc is a provider of artificial intelligence-powered software products, online tools and services to deliver career marketplaces to candidates and employers globally. DHI's brands includes Dice and Clearance Jobs enable recruiters and hiring managers to efficiently search, match and connect with skilled technologists in specialized fields, particularly technology and those with active government security clearances. The company derive the majority of revenue came from the sale of recruitment packages, which allow customers to promote jobs on websites and source candidates through their resume databases. Recruitment packages are typically provided through contractual arrangements with annual, quarterly or monthly payment terms.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.